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Abstract: Nonalcoholic fatty liver disease (NAFLD) is the liver manifestation of the
complex metabolic derangements associated with obesity. NAFLD is characterized by
excessive deposition of fat in the liver (steatosis) and develops when hepatic fatty acid
availability from plasma and de novo synthesis exceeds hepatic fatty acid disposal by
oxidation and triglyceride export. Hepatic steatosis is therefore the biochemical result of an
imbalance between complex pathways of lipid metabolism, and is associated with an array
of adverse changes in glucose, fatty acid, and lipoprotein metabolism across all tissues of
the body. Intrahepatic triglyceride (IHTG) content is therefore a very good marker (and in
some cases may be the cause) of the presence and the degree of multiple-organ metabolic
dysfunction. These metabolic abnormalities are likely responsible for many
cardiometabolic risk factors associated with NAFLD, such as insulin resistance, type 2
diabetes mellitus, and dyslipidemia. Understanding the factors involved in the pathogenesis
and pathophysiology of NAFLD will lead to a better understanding of the mechanisms
responsible for the metabolic complications of obesity, and hopefully to the discovery of
novel effective treatments for their reversal.
Keywords: NAFLD; nonalcoholic fatty liver disease; liver steatosis; glucose metabolism; lipid
metabolism; insulin resistance; obesity; fatty acid metabolism; lipolysis; VLDL secretion

1. Introduction
Obesity is associated with altered physiological functions in almost all tissues and organ systems of
the body. The liver in obese people is characterized by an accumulation of intrahepatic triglyceride
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(IHTG), i.e., steatosis, which is the hallmark feature of nonalcoholic fatty liver disease (NAFLD). This
can progress to nonalcoholic steatohepatitis (NASH) if inflammation is also present, with or without
fibrosis, and can ultimately lead to cirrhosis. Inflammatory markers such as circulating interleukin
(IL)-6, therefore, can discriminate NAFLD from NASH with high specificity [1]. Due to the increased
incidence of obesity worldwide, NAFLD has become an important public health problem because of
its high prevalence, potential progression to severe liver disease, and strong link with important
cardiometabolic risk factors [2]. NAFLD is associated with increased risk for developing insulin
resistance, dyslipidemia (high plasma triglyceride and/or low high density lipoprotein-cholesterol
concentrations), and hypertension [3], and is an independent predictor of the development of pre-diabetes
and type 2 diabetes [4–6]. In this review we provide a concise yet comprehensive assessment of the
complex physiological interactions that adversely affect metabolic function in obesity-related NAFLD.
2. Diagnosis and Prevalence of NAFLD
The defining characteristic of NAFLD is the presence of an increased content of triglyceride within
the cytoplasm of hepatocytes, in the absence of excessive alcohol consumption (defined as >20 g/day
for men and >10 g/day for women) or other causes of fat deposition in the liver (certain medications,
autoimmune or genetic diseases, and viral infections). Excessive hepatic lipid content (i.e., steatosis)
has been traditionally assessed by means of a liver biopsy and defined by chemical means, when IHTG
content exceeds 5% of liver volume or liver weight [7], or by histological means, when 5% of
hepatocytes contain visible intracellular triglyceride [8,9]. In the past decade, advances in imaging
technology allowed the noninvasive evaluation of IHTG content by magnetic resonance spectroscopy
(MRS) in large numbers of subjects [10,11]. Based on MRS measurement of liver fat in a group of
subjects considered to be at low-risk for NAFLD (i.e., subjects of normal weight, with normal fasting
serum glucose and alanine aminotransferase concentrations, and without diabetes mellitus), the upper
“normal” limit of IHTG has been defined as 5.6% of liver volume, which represented the 95th
percentile in this reference population [10]. In most clinical research studies, NAFLD is therefore
defined as IHTG >10% of liver volume. It is important to point out that none of the values proposed
for the diagnosis of NAFLD are based on the relationship between IHTG and either metabolic or
clinical outcomes. In fact, data suggest that the relationship between metabolic function and IHTG
content in obese subjects is linear, without evidence of an obvious threshold that can be used to
define normality [12].
The prevalence rate of NAFLD increases with increasing body mass index (BMI) [13], and is
influenced by age, sex, racial/ethnic background and genetic variation [14–16]. Overall, it is estimated
that ~30% of the adult and ~15% of the pediatric populations in the United States have NAFLD, with a
prevalence rate that reaches ~90% in the severely obese population [17]. The prevalence of NAFLD is
also extremely high in overweight/obese patients with type 2 diabetes (~70%) [18–20] even in the
presence of normal levels of aminotransferases [20].
3. Metabolic Dysfunction in NAFLD
The liver serves as an intermediary organ between exogenous (i.e., dietary) and endogenous sources
of energy and the various extrahepatic organs that consume energy [21], and performs a vast number
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of essential biochemical functions, either continuously or in biological rhythms (e.g., circadian), or
according to specific states (e.g., fasting and feeding) and tissue requirements [22,23], which are
necessary for whole-body metabolic homeostasis [23]. For instance, the liver maintains plasma glucose
concentration within a tightly controlled narrow range, by releasing glucose into the bloodstream in the
postabsorptive state and taking it up in the postprandial state. The liver is also central in normal lipid
and lipoprotein metabolism, by taking up and synthesizing fatty acids, channeling them towards
oxidative or esterification pathways, and secreting them in the form of triglyceride in the core of very
low density lipoproteins (VLDL). NAFLD has been associated with alterations in most of the liver’s
physiological functions.
4. Glucose Metabolism
During the postabsorptive state, when no exogenous carbohydrate is available, endogenous glucose
production (>90% of which comes from the liver) increases to maintain plasma glucose concentration [24].
The rise in endogenous glucose production during fasting is the result of accelerated gluconeogenesis
(the formation of glucose from non-glucose precursors such as lactate, pyruvate, glucogenic amino
acids and glycerol) and glycogenolysis (the degradation of glycogen to glucose units), concomitant to
the low fasting plasma insulin concentration and/or the low insulin/glucagon ratio [24,25]. In healthy
subjects, hepatic gluconeogenesis and glycogenolysis contribute approximately equally to basal
endogenous glucose production [25,26]. After a mixed meal, endogenous glucose production decreases
as a result of the increasing insulin concentration and insulin/glucagon ratio [24]. Hepatic glucose
production is very sensitive to changes in prevailing insulinemia: an increase in insulin concentration
from 11 mU/L (a typical fasting insulin concentration in non-diabetic obese subjects) to only 37 mU/L
causes a 70% decline in hepatic glucose production, whereas at a plasma insulin concentration of 53 mU/L,
hepatic glucose production is suppressed by almost 90% [27]. Insulin inhibits hepatic glucose
production predominantly by stimulating glycogen synthesis (direct pathway) and, to a lesser extent,
by inhibiting proteolysis and lipolysis, thereby limiting the supply of gluconeogenic precursors for
synthesis of new glucose (indirect pathway) [25].
4.1. Hepatic Insulin Action in NAFLD
Many studies have found that hepatic insulin resistance, i.e., the diminished ability of circulating
insulin to suppress hepatic glucose production, is directly related to IHTG content [12,28–31],
independent of age, sex, BMI, waist circumference, percent body fat, and visceral fat mass [12,28,30–33].
For example, individuals with NAFLD have 20% to 35% lower suppression of endogenous glucose
production in response to insulin infusion compared to BMI- and body fat- matched subjects [28,34].
A recent study found that men with high IHTG content have higher flux rates through all three
pathways contributing to glucose production during hyperinsulinemia (gluconeogenesis from
tricarboxylic acid cycle intermediates; gluconeogenesis from glycerol, and glycogenolysis) compared
to those with low IHTG, but no differences during fasting. Consequently, increased production of
glucose during hyperinsulinemia in NAFLD results from inadequate suppression of all the supporting
fluxes of glucose production, rather than from a selective dysregulation of individual glucose
production pathways [35].
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Molecular Mechanisms Linking Hepatic Steatosis to Insulin Resistance
Even though the link between hepatic insulin resistance and NAFLD is well-established, it is still
not known whether NAFLD is the cause, or the consequence, of insulin resistance, or possibly both.
Studies conducted in rodents have found only a few days of high-fat feeding are sufficient to induce
liver steatosis and hepatic insulin resistance, before any change in systemic metabolic function and
inflammation occurs before the development of obesity [36,37]. Experimental treatments such as high
fat feeding or bolus lipid administration promote excessive accumulation of intracellular lipid
intermediates generated by fatty acid metabolism, particularly diacylglycerol (DAG) species, which
provide a putative causal link between increased IHTG content and hepatic insulin resistance. DAG
accumulation in the liver has been shown to activate classical (β) and novel (δ and ε) protein kinase C
isoforms [38–41], which can in fact interfere with insulin action by disrupting normal insulin receptor
function, ultimately leading to impaired insulin-mediated suppression of hepatic glucose production [42].
Recent studies in genetically modified rodents show that PKCβ, PKCδ and PKCε are all independent
regulators of hepatic lipogenic genes and of IHTG accumulation, and that mice lacking any of these
PKC isoforms are protected from high-fat diet induced insulin resistance at the liver but also at the
whole body level [37,39–41,43,44]. In obese human subjects, intrahepatic DAG content, but not
ceramides or acylcarnitines (other derivatives of fatty acid metabolism), is inversely correlated with
the ability of insulin to suppress endogenous glucose production [45]. Similarly, intrahepatic DAG
content correlates with the HOmeostasis Model Assessment (HOMA) score [46], which is a crude
index of hepatic but also muscle insulin resistance [47]. Monoacylglycerol acyltransferase (MGAT)
enzymes, which convert monoacylglycerol to DAG, have recently been considered of potential
relevance to the mechanisms of obesity-related hepatic steatosis because: (i) the product of MGAT
activity (DAG) is a key mediator of insulin resistance in several tissues (see above), (ii) gene
expression of the MGAT enzymes is induced in the steatotic liver of both rodents [48] and
humans [49], and (iii) weight loss in obese subjects causes a reduction in MGAT gene expression
concomitant to an improvement in insulin sensitivity and resolution of hepatic steatosis [49].
Moreover, a recent study in diet-induced obese mice found that inhibition of MGAT activity in the
liver leads to an improvement in glucose tolerance and in hepatic insulin signaling, suggesting that
modulating MGAT activity could represent a possible target to alleviate obesity-associated hepatic
metabolic dysfunction [50].
The endocannabinoid system has also been involved in the development of intrahepatic lipid
accumulation and hepatic insulin resistance. First of all, specific endocannabinoids as well as
endocannabinoid receptors are increased in the liver of mouse models of diet-induced obesity [51].
Moreover, activation of cannabinoid 1 receptor in the liver promotes transcription factors that can
induce de novo lipogenesis and activation of the phosphatidic acid phosphatase, lipin-1 [52]. This can
increase the formation of DAG which can in turn inhibit hepatic insulin action [52]. The endoplasmic
reticulum (ER) stress response has recently been proposed to play a crucial role in the development
and progression of hepatic steatosis, as well as in the pathogenesis of hepatic insulin resistance
associated with NAFLD [53]. Activation of the ER-stress response can induce hepatic steatosis by
activating lipogenic pathways through stimulation of several genes involved in lipid synthesis [53].
Moreover, activation of the ER-stress response induced by an increase in liver saturated fatty acid
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content [54] can cause hepatic insulin resistance through activation of the c-Jun NH2-terminal kinase
(JNK) pathway, which inhibits insulin signaling through inactivation and/or degradation of insulin
receptor substrate (IRS) 1 [55]. The putative role of endoplasmic reticulum stress in mediating
steatosis and hepatic insulin resistance is supported by the observations that ER-stress is increased in
the liver of obese subjects with NAFLD [56], and decreases with weight loss, concomitant to an
improvement in hepatic insulin sensitivity and the resolution of steatosis [57].
Intrahepatic inflammation may also provide a link between NAFLD and insulin resistance. Diet-induced
and genetically-induced obesity in rodent models are associated with hepatic steatosis, insulin
resistance, and increased hepatic nuclear factor (NF)-κB activity [36,58]. Activation of the NF-κB
pathway in the liver causes hepatic inflammation, increases local and circulating interleukin-6 (IL-6),
and results in both hepatic and skeletal muscle insulin resistance [58]. In addition, administration of an
antibody neutralizing IL-6 to mice fed a high-fat diet upregulates skeletal muscle glucose transport and
modulates production of adipose tissue adipokines, ultimately improving hepatic insulin resistance and
steatosis [59]. These observations suggest that steatosis can activate intrahepatic inflammatory
pathways, which upregulate the production of proinflammatory cytokines that can lead to both hepatic
and peripheral insulin resistance. Nevertheless, systemic improvement of inflammatory status can
ameliorate hepatic steatosis by modulating adipokine production and peripheral glucose metabolism.
These findings underscore the complex metabolic interactions between the liver and extrahepatic tissues.
4.2. Muscle Insulin Action in NAFLD
Many studies in human subjects have found that NAFLD is associated not only with impaired
hepatic insulin action, but also with profound insulin resistance in skeletal muscle, i.e., with reduced
ability of circulating insulin to stimulate muscle glucose uptake [12,28–30,32,34]. The presence of
NAFLD is therefore a robust marker of multi-organ insulin resistance and metabolic dysfunction in
obese people [29,32,34,60,61], and may also be a marker of the worsening of metabolic dysfunction in
response to weight gain. A recent study demonstrated that obese people with normal IHTG content are
“protected” from the development of adverse metabolic changes after moderate weight gain (~6% of
initial body weight); conversely, BMI- and body fat mass-matched obese subjects with high IHTG
content (i.e., NAFLD) are prone to further deterioration of insulin action in the liver, adipose tissue,
and skeletal muscle in response to moderate weight gain [34] (Figure 1). Results from this study
demonstrate that IHTG content can be used to identify obese people who are prone to, or protected
from, the development of metabolic disease, at least in response to short-term moderate weight gain.
This suggests that NAFLD can be considered among the criteria to identify obese subjects at a higher
risk of deterioration in metabolic function with additional weight gain, who are therefore in need of
more aggressive weight management therapy. This can potentially have important implications for
public health, not only because the natural history of obesity (i.e., obese people typically gain more
weight and become more obese over time [62]) but also because there is likely a limit of weight gain
beyond which “metabolically-healthy” obese people are no longer protected from a deterioration in
metabolic function [63].
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Figure 1. NAFLD as a marker of metabolic dysfunction. Metabolically-normal (n = 12)
and metabolically-abnormal (n = 8) obese people, defined as having low or high
intrahepatic triglyceride (IHTG) content, respectively, but matched on body mass index
(BMI) and fat mass, were prescribed a hypercaloric diet for 7–8 weeks, until they gained
~6% of their initial body weight. Hepatic insulin sensitivity (top panel) and skeletal muscle
insulin sensitivity (bottom panel), determined by using a two-stage hyperinsulinemiceuglycemic clamp, decreased after weight gain in metabolically-abnormal but not in
metabolically-normal people, suggesting that low liver fat “protects” against the adverse
metabolic effects of moderate weight gain. Drawn with data provided in reference [34].
Values for insulin-mediated suppression of glucose rate of appearance (Ra) are means ±
SEMs, and those for insulin-mediated stimulation of glucose rate of disappearance (Rd) are
back-log-tra nsformed means with 95% confidence intervals. Hepatic and muscle insulin
sensitivity were greater and IHTG content was lower in metabolically-normal than in
metabolically-abnormal people, both before and after weight gain, whereas BMI and fat
mass were not different. * Value after weight gain is significantly different from
corresponding value before weight gain. † Change induced by weight gain (in absolute
terms) is greater in metabolically-abnormal than in metabolically-normal people.
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4.3. β-Cell Dysfunction in NAFLD
Recent studies found that NAFLD is also associated with significant pancreatic β-cell dysfunction
in non-diabetic obese subjects [64,65], but whether this is a primary defect or develops secondarily in
response to insulin resistance is not clear. Individuals with NAFLD have an exaggerated β-cell insulin
secretory response to an oral glucose load independent of BMI, age and sex; and a decline in β-cell
index, which reflects pancreatic β-cell function in the setting of underlying insulin resistance. This
likely reflects deterioration of insulin sensitivity, resulting in augmented insulin secretion to
compensate for the impaired insulin action and maintain glucose homeostasis [65].
4.4. Dissociation between Insulin Resistance and NAFLD
Steatosis does not always coincide with insulin resistance. Studies in rodent models found that
overexpression of hepatic DGAT [66], blockade of hepatic VLDL secretion [67], and pharmacological
blockade of beta-oxidation [68] cause hepatic steatosis but do not impair insulin action; conversely,
inhibition of IHTG synthesis ameliorates hepatic steatosis but does not improve insulin action [69].
Likewise, patients with familial hypobetalipoproteinemia develop hepatic steatosis because of a
genetic deficiency of hepatic apolipoprotein B-100 synthesis, which results in virtually absent
secretion of VLDL particles; however, these individuals do not develop hepatic or peripheral insulin
resistance [70,71]. Therefore, IHTG accumulation does not necessarily cause insulin resistance. It is
thus possible that esterification of surplus fatty acids to biologically inert triglyceride protects the
hepatocyte from the potentially cytotoxic effects of excessive fatty acid availability [72–74]. Along
these lines, IHTG accumulation may be secondary to a primary defect in skeletal muscle insulin action
that diverts carbohydrate from muscle (for storage as muscle glycogen) to the liver (for de novo fatty
acid synthesis) [75]. These findings underscore the complexity of the links between NAFLD and
insulin action and suggest that the relationship between IHTG and multi-organ insulin resistance is
likely multifactorial and certainly not unidirectional.
5. Lipid and Lipoprotein Metabolism
Fat accumulates within hepatocytes when the amount of fatty acids entering the liver (non-esterified
fatty acids taken up from plasma and fatty acids synthesized de novo in hepatocytes) is greater than the
amount of fatty acids exiting (fatty acid oxidation and triglyceride-bound fatty acid secretion) [76].
Therefore, intrahepatic triglyceride content is the net result of complex interactions among various
metabolic pathways: (1) hepatic uptake of plasma free fatty acids (FFA), released mainly from
lipolysis of adipose tissue triglycerides, (2) hepatic de novo lipogenesis, (3) hepatic fatty acid oxidation
and ketogenesis, and (4) fatty acid secretion in VLDL-triglyceride.
5.1. Intrahepatic Fatty Acid Availability in NAFLD
5.1.1. Hepatic Fatty Acid Uptake
Circulating, albumin-bound fatty acids are taken up by hepatocytes via both non-saturable simple
diffusion and saturable facilitated transport. The total uptake of FFA by the liver directly depends on
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the concentration of FFA in plasma, and also on the capacity of hepatocytes for FFA uptake, which is
predominantly related to the number and activity of fatty acid carrier and transport proteins [77].
Facilitated transport accounts for more than two-thirds of total hepatic fatty acid uptake under most
circumstances and is mediated by specialized fatty acid carrier and transport proteins, i.e., fatty acid
binding protein (FABP), fatty acid translocase (FAT/CD36), and fatty acid transport polypeptide
(FATP) [77,78], but also depends on the presence of scaffolding proteins such as caveolin-1 and
lipolytic enzymes, such as phospholipase A2 [76,79]. In the postabsorptive state, the major source of
fatty acids for the liver is the systemic plasma FFA pool, which consists of FFA derived predominantly
from the lipolysis of subcutaneous adipose tissue triglycerides, and to a small extent from lipolysis of
triglyceride in circulating lipoproteins. FFA from the systemic circulation reach the liver through the
hepatic artery and the portal vein after passage through the splanchnic tissues. Although lipolysis of
visceral adipose tissue triglycerides releases additional FFA directly into the portal vein, the relative
contribution of visceral adipose tissue to the total hepatic FFA delivery through the portal vein is quite
small, with only about 5% and 20% of portal vein FFA originating from visceral fat lipolysis in lean
and obese subjects, respectively; the majority of portal vein FFA are derived from subcutaneous
adipose tissue lipolysis after passage through the splanchnic tissues [80]. The modest contribution of
visceral adipose tissue to hepatic FFA delivery casts doubt on its importance in metabolic dysfunction,
and this notion is in line with findings on its contribution to circulating inflammatory markers as well [81].
The basal rate of fatty acid release in the systemic circulation increases directly with increasing
body fat mass in both men and women [82], however, independent of the degree of obesity, the
presence of NAFLD is typically associated with 35%–45% greater basal lipolytic rates [30,60,83,84]
and with impaired insulin-mediated suppression of adipose tissue lipolysis [12,30,83]. These defects in
the regulation of adipose tissue lipolysis are also evident in patients with NASH [85]. Therefore, for a
given amount of body fat, the release of FFA into plasma is greater in patients with NAFLD than those
without NAFLD during both fasting and feeding, i.e., throughout the day [86]. In addition, gene
expression of hepatic lipolytic enzymes, such as hepatic lipase and lipoprotein lipase, are greater in
obese subjects with NAFLD than those without NAFLD [87–89]. These findings suggest that NAFLD
is associated with greater delivery of circulating FFA to the liver. The capacity of the liver to take up
fatty acids is also likely augmented in NAFLD, because of increased hepatic gene expression of
several key proteins involved in lipid uptake and intracellular transport [89]. For instance, hepatic
CD36 mRNA and protein levels are 65%–85% greater in subjects with NAFLD than in BMI-matched
subjects without NAFLD [90], and expression of the FABP isoforms FABP-4 and FABP-5 in the liver
correlates directly with IHTG content [88]. These results highlight the importance of dysregulation of
hepatic fatty acid uptake at many levels, but in a coordinated manner, in the excessive accumulation of
triglyceride in the liver. Nevertheless, not all studies find evidence of upregulated hepatic fatty acid
uptake in NAFLD or NASH [91], suggesting that other factors, perhaps localized inside the liver, are
also likely involved in the pathogenesis of hepatic steatosis.
5.1.2. Hepatic de Novo Lipogenesis
The liver, much like adipose tissue, can synthesize fatty acids intracellularly from simple 2-carbon
precursors (i.e., acetyl-CoA). In a complex polymerization process taking place in the cytoplasm,
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acetyl-CoA carboxylase (ACC) catalyzes the irreversible carboxylation of acetyl-CoA to produce
malonyl-CoA, which then undergoes several cycles of condensation, decarboxylation, and reduction
reactions to form a 16-carbon saturated fatty acid (i.e., palmitate) [92,93]. The synthesis of fatty acids
is catalyzed by fatty acid synthase (FAS), which is a single, large, multifunctional polypeptide enzyme
complex comprising seven distinct enzymatic activities. Regulation of de novo lipogenesis in the liver
occurs: i) by the modulation of the amount and activity of various key enzymatic activities of the
process, including FAS, ACC-1 and ACC-2, AMP-activated protein kinase, diacylglycerol
acyltransferase (DGAT) 1 and 2, and stearoyl-CoA desaturase 1 (SCD1), ii) by the expression and
activation state of nuclear transcription factors, including sterol regulatory element binding proteins
(SREBPs), carbohydrate responsive element binding protein (ChREBP), liver X receptor α (LXRα),
farnesoid X receptor (FXR), and peroxisome proliferator-activated receptors (PPARs), and iii) by the
rate of delivery of acetyl-CoA to the cytoplasm [78,93]. Although several regulatory features of
de novo lipogenesis in the liver are similar to those in adipose tissue [92], there is tissue-specific
regulation which is likely critical for the metabolic dysfunction in obesity and NAFLD [94].
In non-obese healthy subjects, hepatic de novo lipogenesis in the fasting and postprandial states
typically accounts for ≤5% and ≤10% of all fatty acids incorporated in IHTG and VLDL-triglyceride,
respectively [95,96], but its contribution can be as much as 3–5 times greater in patients with NAFLD,
accounting for 15% to 25% of all fatty acids in IHTG and VLDL-triglyceride in the postabsorptive
state [95,97,98]. These results are consistent with the reported upregulation of gene expression of
several of the enzymes involved in hepatic de novo fatty acid synthesis in NAFLD [99–101]. Although
the absolute rates of hepatic de novo lipogenesis in the fasting state are quite small, and thus unlikely
to be primarily responsible for excessive fat accumulation in the liver, these rates increase temporally
in the postprandial state [102] and abnormally large increases in de novo lipogenesis following meal
ingestion may precede the excessive fat accumulation in the liver (i.e., NAFLD) [75]. Specific dietary
habits have been implicated in the augmentation of hepatic de novo lipogenesis and the
development of NAFLD and its progression to NASH (e.g., increased consumption of sugars, such as
fructose [103]), but carefully controlled studies do not support this notion [104,105]. Overall, available
studies highlight a key role for hepatic de novo fatty acid synthesis in IHTG accumulation; however
the observation that increased de novo lipogenesis is not a uniform feature in all individuals with
hepatic steatosis [106] reinforces the importance of other factors in the development and maintenance
of excessive fat accumulation, including those related to liver fat mobilization.
5.2. Intrahepatic Fatty Acid Mobilization in NAFLD
5.2.1. Hepatic Fatty Acid Oxidation and Ketogenesis
Oxidation of fatty acids provides the major source of energy for the liver; together with amino acid
oxidation, it accounts for more than 90% of basal hepatic energy requirements [107]. Fatty acid
oxidation occurs primarily in the mitochondria (beta-oxidation) and to a much lesser extent in
peroxisomes and microsomes (mainly the initial steps of beta-oxidation of very long chain fatty acids,
but also alpha-oxidation) [108]. Beta-oxidation requires fatty acids to be transported from the
cytoplasm to the mitochondrial matrix, i.e., across the mitochondrial double membrane. This process
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requires the “activation” of fatty acids by coenzyme A, which is accomplished by fatty acyl-CoA
synthetase in the cytoplasm [109]. Fatty acyl-CoA is then converted to fatty acyl carnitine by carnitine
palmitoyl transferase (CPT) 1 in the outer mitochondrial membrane, which is then shuttled across the
inner mitochondrial membrane by carnitine translocase [109]. Finally, CPT 2 regenerates fatty acyl
CoA and free carnitine inside the mitochondrial matrix [109]. Beta-oxidation consists of repetitive
cycles of dehydrogenation, hydration, and cleavage reactions, progressively shortening the fatty
acyl-CoA chain by two carbon units per cycle, which are released as acetyl-CoA [110]. Several
membrane-bound and soluble enzymes are involved in this process, varying in acyl chain length
specificity [110]. Under normal circumstances, mitochondrial beta-oxidation is quantitatively the
major pathway of intracellular fatty acid oxidation [108].
Acetyl-CoA generated in the mitochondrial matrix through beta-oxidation enters the tricarboxylic
acid cycle and the electron transport chain, where complete oxidation to carbon dioxide generates
energy for the liver [111]. When oxidation of fatty acids proceeds at very high rates (e.g., during
starvation), acetyl-CoA is produced in excess of the amount that can be disposed in the tricarboxylic
acid cycle; under these conditions, two acetyl-CoA molecules condense to form acetoacetate, which
can be converted to β-hydroxybutyrate or spontaneously turn into acetone (all of which are considered
“ketone bodies”) [111]. Ketone bodies are then released into the bloodstream and provide a source of
energy for extrahepatic tissues, including the skeletal muscle, heart, and brain [109,112,113].
Regulation of beta-oxidation flux can occur at many levels, but largely depends on the rate of delivery
of fatty acids into the mitochondrial matrix, which in turn depends on cytoplasmic fatty acid
availability and the activity of CPT1 [114]. A long-known inhibitor of CPT1 is malonyl-CoA that is
produced by the carboxylation of acetyl-CoA during de novo lipogenesis [115]. Regulation of
ketogenesis depends on all factors controlling beta-oxidation and the ratio of acetyl-CoA to free CoA
in the mitochondrial matrix [111]. The two main pathways of intracellular fatty acid metabolism
(de novo lipogenesis and beta-oxidation/ketogenesis) proceed at opposite directions under tight
metabolic control, so that when one direction is favored, the other is inhibited.
Given that hepatic de novo lipogenesis is augmented in NAFLD [95,97,98], it is not unreasonable to
expect that hepatic beta-oxidation/ketogenesis would be suppressed [116]. Data from studies
conducted in rodent models demonstrate that modulation (up- or down-regulation) of intrahepatic fatty
acid oxidation by a variety of means influences IHTG content. Genetic or experimentally-induced
deficiency of enzymes involved in mitochondrial beta-oxidation leads to accumulation of IHTG [117,118],
and vice versa [119–123]. Studies in human subjects, however, provide controversial results, and their
interpretation is further complicated by the absence of a reliable method to directly measure fatty acid
oxidation in the liver in vivo. Hepatic CPT1 gene expression is typically lower, but gene expression of
several other key enzymes of hepatic fatty acid oxidation is actually greater in subjects with NAFLD
than those with normal IHTG content [89,99–101]. Other indirect measures of fatty acid oxidation in
the liver, such as plasma ketone body concentrations, suggest that hepatic fatty acid oxidation is either
normal or increased in people with NAFLD [29,30,124,125]. Nevertheless, circulating ketone bodies
are likely an unreliable marker of hepatic fatty acid oxidation, given the unstable chemical nature of
ketone bodies (leading to their rapid interconversion and/or conversion to acetone) but also the fact
that their plasma concentrations reflect the net balance between the rate of hepatic ketogenesis and the
rates of extrahepatic ketone body utilization. Early tissue perfusion studies reported that hepatic
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ketogenesis could be an important determinant of IHTG accumulation, as it can dispose of as much as
two-thirds of the fat entering the liver [126]. However, a recent study in an knockout rodent model
demonstrated that impaired hepatic ketogenesis can be an important determinant of NAFLD
progression to NASH, but not NAFLD development itself [127], and the only available study to date
that measured rates of ketogenesis in vivo in human subjects, by means of β-hydroxybutyrate tracer
dilution, found no differences between subjects with and without NAFLD, matched for BMI and
percent body fat [84].
Interestingly, it has been reported that NAFLD is associated with hepatic mitochondrial structural
and functional abnormalities, including loss of mitochondrial cristae and paracrystalline
inclusions [29,128], decreased mitochondrial respiratory chain activity [129], impaired ability to
resynthesize ATP following a fructose challenge [130], and increased hepatic uncoupling protein 2 [100].
All of these abnormalities could affect hepatic energy production but not fatty acid oxidation, and
could represent an adaptive uncoupling of fatty acid oxidation and ATP production, which allows the
liver to oxidize excessive fatty acid substrates without generating unneeded ATP. The summation of
these observations likely refutes the decrease in hepatic fatty acid oxidation as a major contributor to
IHTG accumulation and the pathogenesis of NAFLD in humans. In addition, data from animal studies
and in vitro experiments suggest there are several rescue pathways of fatty acid oxidation in conditions
of insufficient mitochondrial beta-oxidation, including peroxisomal fatty acid oxidation and
omega-oxidation [108,131]. Very little—if anything—is known regarding these pathways of fatty
acid utilization in NAFLD, although there are some reports of augmented expression of peroxisomal
(beta-oxidation) and microsomal (omega-oxidation) enzymes of fatty acid oxidation in liver samples
from patients with NAFLD than those without NAFLD [100].
5.2.2. Hepatic VLDL-triglyceride Secretion
An important pathway of mobilization of liver fat consists of triglyceride export in the hydrophobic
core of VLDL. Hepatic VLDL assembly occurs in two steps, both of which require the action of
microsomal triglyceride transfer protein (MTP) [132]. The process involves the partial lipidation of a
newly synthesized apolipoprotein B-100 molecule to form a small and dense VLDL precursor (first step),
and the fusion of this small and dense precursor with a large triglyceride droplet to form a mature and
triglyceride-rich VLDL (second step), which is subsequently secreted into plasma [132]. Each VLDL
particle contains a single molecule of apolipoprotein B-100 [133], which is a large polypeptide that
provides and maintains the structure of the whole lipoprotein particle and remains bound to the VLDL
throughout its intravascular metabolism; whereas the availability of triglyceride in the core of nascent
VLDL varies considerably (from ~5000 to ~50,000 in human subjects in vivo) and can determine some
aspects of the metabolic fate of VLDL [134].
Fatty acids are made available to the liver from several sources. The major source of hepatic fatty
acids is the systemic plasma FFA pool, which consists of fatty acids derived predominantly from
subcutaneous adipose tissue lipolysis; fatty acids are made available to the liver from several
nonsystemic sources as well, including hepatic de novo lipogenesis and lipolysis of triglyceride already
stored in the liver (intrahepatic fat) and intra-abdominal adipose tissue (visceral fat), or carried back to
the liver after lipoprotein uptake (e.g., LDL and HDL) [135]. In healthy postabsorptive subjects, the
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majority (65%–75%) of fatty acids utilized for hepatic VLDL-triglyceride secretion are derived from
the systemic plasma FFA pool; a small portion (<5%) originates from hepatic de novo lipogenesis,
with the remainder (20%–30%) likely originating from the lipolysis of intrahepatic, visceral, and
circulating lipoprotein triglyceride [136,137]. Fatty acids that are not oxidized in the liver are esterified
to triglyceride, which can either be stored within the hepatocyte or incorporated into VLDL and
secreted into the circulation. The precise mechanisms controlling the channeling of fatty acids towards
storage or secretion are not entirely clear, however their origin (e.g., synthesized de novo, or taken up
from plasma, or derived from lipolysis of stored triglyceride) may be an important factor [138,139].
In any case, by providing a mechanism for triglyceride export, VLDL secretion could be a means to
reduce IHTG accumulation. Conversely, impaired hepatic VLDL secretion caused by genetic defects
(familial hypobetalipoproteinemia) [140], pharmacological agents that inhibit MTP [141] or VLDL
sorting through the Golgi apparatus [142], or deletion of CD36 [143], is associated with increased
IHTG content. Surprisingly, data from most [60,144] but not all [95] studies in human subjects
indicate that NAFLD is associated with a marked increase in hepatic VLDL-triglyceride secretion rate,
independent of BMI and percent body fat. The majority of this increase is accounted for by a marked
increase in the secretion of VLDL-triglyceride from nonsystemic fatty acids, presumably derived from
the lipolysis of intrahepatic and visceral fat and de novo lipogenesis [60]. These findings demonstrate
that increased IHTG content results in oversecretion of VLDL-triglyceride; however the increase in
hepatic VLDL-triglyceride secretion is not sufficient to prevent or reverse NAFLD. This notion is
supported by the observation that hepatic VLDL-triglyceride secretion rate increases linearly with
increasing IHTG content within the normal range (up to 5%–10% of liver volume), but plateaus
thereafter with IHTG content within the NAFLD range (>10% of liver volume) [60].
The mechanism(s) responsible for the inadequate increase in hepatic VLDL-triglyceride export in
NAFLD is not known. The secretion rate of VLDL-apolipoprotein B-100 from the liver, which directly
reflects the secretion of VLDL particles themselves (since each VLDL particle contains one molecule
of apolipoprotein B-100), is either not different [60] or only slightly greater [145] in subjects with
NAFLD than those without NAFLD. Hence the molar ratio of VLDL-triglyceride secretion rate to
VLDL-apolipoprotein B-100 secretion rate, which is an index of the triglyceride content (and
therefore, of the size) of newly-secreted VLDL particles from the liver, is more than two-fold greater
in people with NAFLD [60]. These results suggest the liver in NAFLD secretes triglyceride-richer and
larger in size VLDL. Studies in rodents found that very large VLDL particles cannot be secreted from
the liver because they exceed the diameter of the sinusoidal endothelial pores, and this inability can
result in excessive IHTG accumulation and the development of steatosis [146]. On the contrary,
pharmacological induction of apolipoprotein B-100 secretion can help reduce triglyceride
accumulation in hepatocytes [147]. It therefore seems an imbalance between the secretion of
VLDL-triglyceride and VLDL-apolipoprotein B-100, resulting from a “failure” to sufficiently
upregulate hepatic VLDL-apolipoprotein B-100 secretion to match the excess VLDL-triglyceride
secretion, is central in the development and maintenance of NAFLD associated with obesity. This is not the
case when fatty liver occurs outside the context of obesity, e.g., in protein-energy malnutrition [148].
Apolipoprotein B-100 is typically synthesized in hepatocytes at rates that far exceed those required for
VLDL secretion; in fact the majority of the protein produced is recycled intracellularly [149],
suggesting that the rate of degradation likely controls the amount of apolipoprotein B-100 available for
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secretion. An increasing body of evidence suggests that hepatic ER stress, induced by the oversupply
of fatty acids, augments intracellular proteolysis of apolipoprotein B-100 and thereby reduces the
secretion of VLDL-apolipoprotein B-100 [147,150,151]. The metabolic inability to secrete more
VLDL particles (to export more triglyceride in more particles) in conjunction with the physical
inability to secrete larger and larger VLDL particles (to export more triglyceride per particle) are likely
important contributing factors to excessive IHTG accumulation and potentially to the development
of NAFLD.
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Figure 2. Mechanisms of metabolic dysfunction in NAFLD. Nonalcoholic fatty liver
disease (NAFLD) is associated with increased release of free fatty acids (FFA) from
adipose tissue, because of enlarged fat stores and the inability of insulin to down-regulate
lipolysis (i.e., adipose tissue insulin resistance); systemic plasma FFA are subsequently
taken up by the liver at increased rates. Intrahepatic fatty acid availability is further
augmented by increased hepatic de novo lipogenesis (DNL). Increased availability of fatty
acids in the liver results in accumulation of intrahepatic triglyceride (TG) and steatosis,
oversecretion of very low density lipoprotein (VLDL) TG and various form of
dyslipidemia, and increased glucose production (i.e., hepatic insulin resistance). Increased
availability of fatty acids in muscle results in decreased glucose uptake (i.e., skeletal
muscle insulin resistance). The net result of increased glucose production and decreased
glucose uptake is an increase in plasma glucose concentration (hyperglycemia), which
stimulates the pancreas to secrete more insulin, to compensate for the impaired insulin
action. Hyperglycemia and hyperinsulinemia further augment hepatic de novo lipogenesis.
6. Conclusions
Hepatic steatosis (i.e., NAFLD) is a common feature of obesity and is associated with a plethora of
metabolic abnormalities including: (1) multi-organ insulin resistance, reflected by the inability of

Nutrients 2015, 7

5008

insulin to downregulate hepatic glucose production (liver insulin resistance) and subcutaneous adipose
tissue lipolysis (adipose tissue insulin resistance), and to stimulate muscle glucose uptake (skeletal
muscle insulin resistance), (2) increased pancreatic β-cell insulin secretion to compensate for the
impaired insulin action, (3) increased intrahepatic fatty acid availability from systemic (i.e., plasma)
and nonsystemic (e.g., de novo lipogenesis) sources, and (4) increased hepatic triglyceride export in
the form of VLDL, which leads to various forms of dyslipidemia (Figure 2). Despite the progress that
has occurred in recent years in the understanding much of the pathophysiology of NAFLD, it still
remains unclear whether the presence of liver steatosis is a cause or a consequence of metabolic
dysfunction. It is likely that both possibilities are true, so that different initiating events can lead to the
same adverse metabolic spiral of excessive IHTG accumulation and deteriorated metabolic function.
There is no doubt, however, that hepatic steatosis is a robust marker of metabolic dysfunction:
increased IHTG content is a better marker of multi-organ insulin resistance and oversecretion of
VLDL-triglyceride than whole-body or visceral adiposity [32,152], and predicts adverse metabolic
changes induced by moderate weight gain [34]. A better characterization of the complex metabolic
interactions leading to, or resulting from, hepatic steatosis will lead to the identification of novel
therapeutic targets that can be manipulated by lifestyle (e.g., diet and exercise [153]) or pharmacological
interventions to prevent or reverse hepatic steatosis and its unfavorable metabolic sequalae.
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